TRADES
Latest Trades
3504
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 25 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 17,500 0.0221
ARKG 25 Nov 2022 Sell ONVO ORGANOVO HOLDINGS INC 1,856 0.0001
ARKG 22 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 5,000 0.0062
ARKG 22 Nov 2022 Buy PRME PRIME MEDICINE INC 23,313 0.0183
ARKG 22 Nov 2022 Sell ONVO ORGANOVO HOLDINGS INC 1,239 0.0001
ARKG 21 Nov 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 4,394 0.0592
ARKG 21 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 15,000 0.0183
ARKG 21 Nov 2022 Buy QSI QUANTUM 563,250 0.0705
ARKG 21 Nov 2022 Buy PRME PRIME MEDICINE INC 31,654 0.0242
ARKG 21 Nov 2022 Sell ONVO ORGANOVO HOLDINGS INC 68 0.0000
ARKG 21 Nov 2022 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 14,014 0.0039
ARKG 21 Nov 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 3,031,443 0.2683
ARKG 18 Nov 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 10,337 0.1372
ARKG 18 Nov 2022 Buy QSI QUANTUM 13,727 0.0017
ARKG 18 Nov 2022 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 458,104 0.1241
ARKG 18 Nov 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,026,053 0.0933
ARKG 17 Nov 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 10,117 0.1300
ARKG 17 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 80,000 0.0945
ARKG 17 Nov 2022 Sell ONVO ORGANOVO HOLDINGS INC 2,467 0.0002
ARKG 17 Nov 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,291,724 0.1120
ARKG 16 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 64,502 0.0737
ARKG 15 Nov 2022 Buy TWST TWIST BIOSCIENCE CORP 16,974 0.0197
ARKG 15 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 84,866 0.0972
ARKG 15 Nov 2022 Sell ONVO ORGANOVO HOLDINGS INC 5,185 0.0003
ARKG 15 Nov 2022 Buy MASS 908 DEVICES INC 45,601 0.0218
ARKG 14 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 25,000 0.0281
ARKG 14 Nov 2022 Buy MASS 908 DEVICES INC 173,832 0.0863
ARKG 11 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 15,196 0.0183
ARKG 11 Nov 2022 Sell ONVO ORGANOVO HOLDINGS INC 1,606 0.0001
ARKG 9 Nov 2022 Buy SDGR SCHRODINGER INC 64,385 0.0581
ARKG 9 Nov 2022 Buy QSI QUANTUM 79,408 0.0087
ARKG 8 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 25,383 0.0336
ARKG 8 Nov 2022 Buy SDGR SCHRODINGER INC 61,975 0.0581
ARKG 8 Nov 2022 Buy QSI QUANTUM 3,733 0.0004
ARKG 8 Nov 2022 Buy PRME PRIME MEDICINE INC 4,560 0.0037
ARKG 8 Nov 2022 Sell ONVO ORGANOVO HOLDINGS INC 400 0.0000
ARKG 7 Nov 2022 BUY VERV VERVE THERAPEUTICS INC 137,658 0.1443
ARKG 7 Nov 2022 BUY TWST TWIST BIOSCIENCE CORP 30,951 0.0433
ARKG 7 Nov 2022 SELL SGFY SIGNIFY HEALTH INC 50,000 0.0641
ARKG 7 Nov 2022 BUY SDGR SCHRODINGER INC/UNITED STATES 36,321 0.0327
ARKG 7 Nov 2022 BUY QSI QUANTUM-SI INC 29,470 0.0031
ARKG 7 Nov 2022 BUY PSNL PERSONALIS INC 63,000 0.0069
ARKG 7 Nov 2022 BUY PRME PRIME MEDICINE INC 30,902 0.0244
ARKG 4 Nov 2022 Buy TWST TWIST BIOSCIENCE CORP 22,162 0.0308
ARKG 4 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 25,000 0.0318
ARKG 4 Nov 2022 Buy SDGR SCHRODINGER INC 147,747 0.1409
ARKG 4 Nov 2022 Buy QSI QUANTUM 83,639 0.0090
ARKG 4 Nov 2022 Buy PSNL PERSONALIS INC 280,100 0.0307
ARKG 4 Nov 2022 Buy CDNA CAREDX INC 42,283 0.0311
ARKG 3 Nov 2022 Buy TWST TWIST BIOSCIENCE CORP 9,300 0.0126
ARKG 3 Nov 2022 Sell SGFY SIGNIFY HEALTH INC 25,000 0.0317
ARKG 3 Nov 2022 Buy SDGR SCHRODINGER INC 3,281 0.0034
ARKG 3 Nov 2022 Buy QSI QUANTUM 731,788 0.0840
ARKG 3 Nov 2022 Buy PSNL PERSONALIS INC 95,571 0.0109
ARKG 3 Nov 2022 Sell IONS IONIS PHARMACEUTICALS INC 190,606 0.3676
ARKG 3 Nov 2022 Buy CDNA CAREDX INC 48,326 0.0392
ARKG 3 Nov 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 227,348 0.0768
ARKG 2 Nov 2022 Buy TWST TWIST BIOSCIENCE CORP 53,900 0.0737
ARKG 2 Nov 2022 Buy SDGR SCHRODINGER INC 2,026 0.0020
ARKG 2 Nov 2022 Buy QSI QUANTUM 26,501 0.0032
ARKG 2 Nov 2022 Sell IONS IONIS PHARMACEUTICALS INC 51,310 0.0972
ARKG 2 Nov 2022 Buy CMPS COMPASS PATHWAYS PLC 138,640 0.0601
ARKG 2 Nov 2022 Buy CDNA CAREDX INC 168,762 0.1372
ARKG 2 Nov 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 235,319 0.0779
ARKG 1 Nov 2022 Buy TWST TWIST BIOSCIENCE CORP 23,300 0.0329
ARKG 1 Nov 2022 Buy SDGR SCHRODINGER INC 805 0.0008
ARKG 1 Nov 2022 Sell IONS IONIS PHARMACEUTICALS INC 65,329 0.1248
ARKG 1 Nov 2022 Buy CDNA CAREDX INC 20,310 0.0172
ARKG 31 Oct 2022 Buy SDGR SCHRODINGER INC 40,084 0.0400
ARKG 31 Oct 2022 Sell ONVO ORGANOVO HOLDINGS INC 800 0.0001
ARKG 31 Oct 2022 Sell IONS IONIS PHARMACEUTICALS INC 15,959 0.0297
ARKG 31 Oct 2022 Buy CMPS COMPASS PATHWAYS PLC 20,102 0.0088
ARKG 28 Oct 2022 Sell SGFY SIGNIFY HEALTH INC 25,000 0.0317
ARKG 28 Oct 2022 Buy PSNL PERSONALIS INC 10,800 0.0012
ARKG 28 Oct 2022 Sell ONVO ORGANOVO HOLDINGS INC 599 0.0000
ARKG 28 Oct 2022 Sell IONS IONIS PHARMACEUTICALS INC 86,543 0.1676
ARKG 28 Oct 2022 Buy CDNA CAREDX INC 24,210 0.0203
ARKG 28 Oct 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 14,879 0.0048
ARKG 27 Oct 2022 Sell SGFY SIGNIFY HEALTH INC 35,000 0.0436
ARKG 27 Oct 2022 Buy SDGR SCHRODINGER INC 20,817 0.0204
ARKG 27 Oct 2022 Buy PSNL PERSONALIS INC 9,076 0.0010
ARKG 27 Oct 2022 Buy PRME PRIME MEDICINE INC 5,736 0.0039
ARKG 27 Oct 2022 Sell ONVO ORGANOVO HOLDINGS INC 133 0.0000
ARKG 27 Oct 2022 Buy CMPS COMPASS PATHWAYS PLC 5,000 0.0021
ARKG 27 Oct 2022 Buy CDNA CAREDX INC 36,611 0.0301
ARKG 27 Oct 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 82,944 0.0260
ARKG 25 Oct 2022 Sell SGFY SIGNIFY HEALTH INC 50,860 0.0683
ARKG 25 Oct 2022 Buy SDGR SCHRODINGER INC 12,594 0.0130
ARKG 25 Oct 2022 Buy PRME PRIME MEDICINE INC 42,101 0.0307
ARKG 25 Oct 2022 Sell ONVO ORGANOVO HOLDINGS INC 1,635 0.0001
ARKG 25 Oct 2022 Sell IONS IONIS PHARMACEUTICALS INC 18,243 0.0379
ARKG 25 Oct 2022 Buy CDNA CAREDX INC 500 0.0004
ARKG 24 Oct 2022 Buy TWST TWIST BIOSCIENCE CORP 4,201 0.0054
ARKG 24 Oct 2022 Sell SGFY SIGNIFY HEALTH INC 175,000 0.2319
ARKG 24 Oct 2022 Buy SDGR SCHRODINGER INC 1,693 0.0017
ARKG 24 Oct 2022 Buy QSI QUANTUM 34,074 0.0041
ARKG 24 Oct 2022 Buy PSNL PERSONALIS INC 34,600 0.0035
ARKG 24 Oct 2022 Buy PRME PRIME MEDICINE INC 302,349 0.2087
ARKG 24 Oct 2022 Sell IONS IONIS PHARMACEUTICALS INC 108,656 0.2215
ARKG 24 Oct 2022 Buy CDNA CAREDX INC 26,562 0.0202
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.